|
BP702001 and BP703010, next generation multi targets Kinase inhibitors
Diseases such as cancer employ multiple strategies to survive involving various cellular signaling pathways that promote their transformation and growth. Cancer cells can rapidly evade drugs that are highly specific for a target within one of these pathways through the development of resistance mechanisms. If more than one of these redundant signaling pathways can be interrupted at once, then the chance for resistance to develop is greatly reduced. Betapharma’s drug candidates act by attacking cancer cells through multiple pathways that promote the formation and replication of tumor cells, while also interrupting the formation of blood vessels that nourish and sustain tumor growth.
|
